Jul. 28 at 6:31 PM
$SLS SLS will be Bought for close to
$40B -- will Still allow plenty of Upside for
$LLY /
$ABBV
* Gps Phase 2 MOS for CR1 - First Remission Patients Absent transplant was not yet reached and > 67.6 Months.
Dr. K and the MDACC team published Benchmark CR1 MOS of 19 months.
Gps > 67.6 VS BAT 19 --- It is NOT COMPLICATED
This is a look at the CR1 Market Opportunity:
40,000 Patients a Year in the US/Eu/Japan
$300K rev per Patient year 1 / 5 Year Anticipated Dosing.
